The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.
Kelly F. Bell, PharmD, MSPhr
Advertisement
Articles by Kelly F. Bell, PharmD, MSPhr
Advertisement
Latest Updated Articles
- A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes
Published: April 14th 2018 | Updated:
- Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population
Published: April 14th 2018 | Updated:
- Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”
Published: April 8th 2019 | Updated:
Advertisement
Advertisement
